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ORIGINAL ARTICLE
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ABSTRACT Objective: European lung cancer  screening studies  using  computed tomography (CT) have  shown that  a  management  protocol
based on measuring lung nodule volume and volume doubling time (VDT) is more specific for early lung cancer detection than a
diameter-based  protocol.  However,  whether  this  also  applies  to  a  Chinese  population  is  unclear.  The  aim  of  this  study  is  to
compare  the  diagnostic  performance  of  a  volume-based protocol  with  a  diameter-based protocol  for  lung cancer  detection and
optimize the nodule management criteria for a Chinese population.
Methods: This study has a population-based, prospective cohort design and includes 4000 participants from the Hexi district of
Tianjin,  China.  Participants  will  undergo low-dose chest  CT at  baseline and after  1  year.  Initially,  detected lung nodules  will  be
evaluated for diameter and managed according to a routine diameter-based protocol (Clinical Practice Guideline in Oncology for
Lung  Cancer  Screening,  Version  2.2018).  Subsequently,  lung  nodules  will  be  evaluated  for  volume  and  management  will  be
simulated according to a volume-based protocol and VDT (a European lung nodule management protocol). Participants will be
followed up for 4 years to evaluate lung cancer incidence and mortality. The primary outcome is the diagnostic performance of the
European volume-based protocol compared to diameter-based management regarding lung nodules detected using low-dose CT.
Results: The diagnostic performance of volume- and diameter-based management for lung nodules in a Chinese population will
be estimated and compared.
Conclusions: Through the  study,  we  expect  to  improve  the  management  of  lung  nodules  and  early  detection  of  lung  cancer  in
Chinese populations.
KEYWORDS Lung cancer; lung nodules; screening; computed tomography; China
 
Introduction
Lung cancer is  the fourth most common cause of death and
the most common type of cancer in China1 . More than one-
third  of  global  lung  cancer  diagnoses  (733.3  thousand  in
2015)  and  lung-cancer-related  deaths  (610.2  thousand  in
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2015)  occur  in  China2.  The  estimated  age-standardized
mortality rate in 2008 for lung cancer was 28.7 per 100,  000
in  China,  which  is  considerably  higher  than  the  world
average (19.4 per 100, 000)3,4. The high mortality rate of lung
cancer  is  mainly  attributable  to  the  known  risk  factors  of
tobacco  smoking  (68%),  occupational  agents  (9.5%),  and
indoor  radon (0.2%)5.  Lung cancer  is  predicted  to  continue
to  be  a  major  public  health  issue  in  the  future  because  of
large number of smokers (316 million according to the 2015
China Adult Tobacco Survey)6 and population aging7.
Lung  cancer  is  commonly  diagnosed  and  treated  at  a
relatively late stage, often after the first clinical symptoms
occur8,  and consequently  has  poor  survival  outcomes9,10.
Numerous clinical trials conducted in the United States and
Europe have provided growing evidence that screening with
low-dose CT is efficient for early diagnosis of lung cancer11.
The  U.S.  National  Lung  Screening  Trial  showed  that
screening with  low-dose  CT leads  to  a  20% lower  risk  of
dying from lung cancer compared to chest radiography12.
Accordingly,  there  is  an  urgent  need  to  implement  an
efficient lung cancer screening protocol in China, which is
expected to reduce mortality and the burden caused by lung
cancer. Although evidence exists for the role of CT in lung
cancer screening12, investigations are currently underway to
optimize  nodule  management  and reduce  the  number  of
false-positive  screening  results13-15.  Various  lung  cancer
screening guidelines recommend nodule management based
on manually measured nodule diameter16-18. However, a lung
nodule management protocol based on nodule volume and
volume  doubling  time  (VDT)  is  more  specific  for  early
detection of lung cancer19 compared to the diameter-based
protocol of the American College of Chest Physicians, with a
specificity  of  94.9%  vs.  90.0%,  respectively,  at  a  similar
sensitivity of 90.9%13,20. We designed a study to be conducted
in  Tianjin,  China,  to  validate  the  findings  of  a  previous
European study and demonstrate the diagnostic performance
of  a  volume-based  nodule  management  protocol  as
compared  with  a  diameter-based  protocol  for  the




The study includes 4,000 participants who meet the following
inclusion  criteria:  aged  40–74  years,  resident  in  the  Hexi
district of Tianjin city for at least 3 years, and having no self-
reported  history  of  any  malignant  tumor.  The  inclusion
criteria  were  assessed  by  a  doctor  in  a  community  health
service center (CHSC) during a face-to-face interview.
A recruitment campaign was conducted in the first quarter
of 2017 by distributing advertisements such as video media
(e.g., TV news), text media (e.g.,  newspapers), new media
(e.g.,  WeChat),  poster,  leaflets,  and free consultations,  in
which the participation criteria and time were announced.
Between  May  and  October  2017,  2,400  eligible  residents
visited the Yuexiu Street and Youyi Street CHSCs and agreed
to participate. The remaining 1,600 volunteers were invited
to visit the Yuexiu Street, Youyi Street, and Chentangzhuang
Street CHSCs between April and September 2018.
Study design
In  this  population-based  prospective  cohort  study,
participants  underwent  a  low-dose  chest  CT  scan. Figure  1
presents an overview of the study design. At baseline, the first
CT scan was performed in all participants and their data were
collected.  One-year after  the baseline,  a  second CT scan will
be  performed  and  data  will  be  collected  again.  Participants
will  be  followed up for  4  years  in  total  and any diagnosis  of
lung cancer and related information will be collected through
the  hospital  information  system  and  by  contacting  the
participants  or  their  relatives  at  the  end  of  follow-up.  This
study  is  performed  at  Tianjin  Medical  University  Cancer
Institute and Hospital (TJMUCIH), and will be embedded in
the larger NELCIN-B3 study21.
CT image acquisition and reading
Participants  undergo  a  CT  scan  in  the  Department  of
Radiology at TJMUCIH after an interview in one of the three
regional CHSCs. All scans are performed using the same CT
system:  Definition  AS  (Somaton  Definition  AS  64,  Siemens,
Erlangen, Germany). The total radiation dose is a maximum
of  2  mSv.  Positioning  of  participants  is  head-first,  supine,
and with arms above the head. The CT scan is performed at
inspiration  with  the  following  parameters:  (a)  spiral  scan
mode  at  120  kVp  and  with  a  reference  tube  current  of
35 mAs; (b) three reconstruction kernels:  D45F and B80F at
1.0/0.7  mm  thickness/increment  and  B30  at  2.0/1.0  mm
thickness/increment.
CT  images  of  each  participant  will  be  read  twice
independently by two groups of readers after the baseline and
1-year  follow-up  scans.  The  clinical  management  of
participants will be based on the first reading.
First reading
The CT images obtained from the baseline and 1-year follow-
up scans will be read by one of four specially trained Chinese
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resident  radiologists  and  checked  by  one  of  two  senior
Chinese  radiologists  at  TJMUCIH,  using  the  Carestream
Picture  Archiving  and  Communication  Systems  (PACS)  v.
11.0.  A  complete  list  of  the  nodule  parameters  that  will  be
collected is presented in Appendix 1. Lung Cancer Screening
(version  2.  2018)  in  the  Clinical  Practice  Guidelines  in
Oncology  of  the  National  Comprehensive  Cancer  Network
(NCCN) will be used for the management of lung nodules16.
This  guideline  recommends  management  of  lung  nodules
based on their diameters. Participants with a detected solid or
part-solid nodule ≤ 5 mm in diameter or non-solid nodule ≤
19  mm  in  diameter  will  be  referred  to  undergo  follow-up
thorax  CT  1  year  after  the  baseline.  Participants  with  a
detected  solid  nodule  6–7  mm  in  diameter  or  part-solid
nodule ≥ 6 mm in diameter with a solid component ≤ 5 mm
in diameter or a non-solid nodule ≥ 20 mm in diameter will
be  referred  to  undergo  follow-up  thorax  CT 6  months  after
the  baseline.  Participants  with  a  detected  solid  nodule  8–14
mm in diameter or a part-solid nodule ≥ 6  mm in diameter
with a solid component 6–7 mm in diameter will be referred
to undergo follow-up thorax CT 3 months after the baseline.
Finally, participants with a detected solid nodule ≥ 15 mm in
diameter or  a  part-solid nodule with a  solid component ≥ 8
mm in diameter  will  be  referred to a  multidisciplinary team
for clinical investigation and, if applicable, treatment.
Second reading
During  the  second  reading,  each  scan  will  be  interpreted
again  by  radiologists  with  experience  in  lung  cancer
screening,  who  will  be  blinded  to  the  first  reading.  Semi-
automated  volumetry  software  (MM  Oncology  Syngo.  via
VB10B,  Siemens  Healthcare,  Forchheim,  Germany)  will  be
used  to  measure  the  volume  and  evaluate  the  other
parameters  (diameter,  location,  edge,  shape,  density,
calcification, attachment) of the lung nodules (Appendix 1).
Solid and part-solid lung nodules
Based  on  the  results  of  the  second  reading,  solid  and  part-
solid lung nodules (solid component visible in a mediastinal
window setting) will be reclassified according to the reference
values  from  the  European  volume-based  lung  nodule
management protocol11 and the management of the nodules
will be modeled on this protocol. According to the European
volume-based protocol, the solid and part-solid lung nodules
will  be reclassified into three groups: nodules with a volume
<  100  mm3 (negative  results),  nodules  with  a  volume  of
100–300  mm3 (indeterminate  results),  and  nodules  with  a
volume > 300 mm3 (positive results)11,13. In case of part-solid
nodules,  only  the  volume  of  the  solid  component  will  be
measured.
Solid and part-solid lung nodules detected at baseline will
be managed as follows: (1) for negative results:  a CT scan
1 year after the baseline; (2) for those with intermediate-sized
nodules: a follow-up CT scan 3 months after the baseline to
calculate the VDT for further assessment; and (3) for those
with a positive result: referral to a multidisciplinary team for
further clinical investigation and, if applicable, treatment.
 
Figure 1   Design of methods of computed tomography screening and management of lung cancer in Tianjin.
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The assessment of intermediate-sized nodules is based on
VDT, which will be calculated based on the 3–6-month or
1-year follow-up scans. A fast VDT (< 400 days) indicates a
positive screening result, a VDT of 400–600 days indicates an
indeterminate  screening  result,  and  a  VDT  ≥  600  days
indicates a negative screening result.
In  the  volume-based  nodule  management  model,
participants  with  negative  and indeterminate  results  will
undergo a CT scan 1 year after the baseline. Solid and part-
solid nodules newly detected at the one-year follow-up scan
must be followed up 1–3 months later.
Non-solid lung nodules
Non-solid nodules can be further classified into homogenous
non-solid  nodules  (also  considered  pure  ground  glass
nodules)  and  heterogeneous  non-solid  nodules.
Heterogeneous  non-solid  nodules  have  solid  components  in
a  lung  window  setting  but  not  in  a  mediastinal  window
setting.  When  the  diameter  of  the  solid  part  observed  in  a
mediastinal window setting exceeds 0 mm, the nodule should
be classified as part-solid and managed accordingly22.
No validated protocol  currently  exists  for  the  volume-
based management  of  non-solid  nodules.  In  recent  years
however,  software  for  the  semi-automated  volumetric
analysis of non-solid nodules has been improved, thereby
enabling a volumetric approach to non-solid nodules, similar
to the volume-based management of  solid and part-solid
nodules.
In the second reading, we will assess the volume of non-
solid nodules by using semi-automated volumetry in MM
Oncology Syngo. via. The mass will be calculated using the
formula M = V x (HUmean + 1000)/1000, where M is mass
(mg/mL),  V  is  volume  (mm3),  and  HUmean  is  the  mean
attenuation in Hounsfield units.
For  both  homogenous  and  heterogeneous  non-solid
nodules with a volume < 1,125 mm3, regular follow-up scans
after 12 months are recommended to evaluate appearance of
the solid components. When the volume exceeds 1,125 mm3,
follow-up at 6 months is recommended23.
On follow-up CT, both volume and mass  will  again be
assessed and VDT and mass doubling time (MDT) will be
calculated. If follow-up CT reveals solid components (visible
in a mediastinal window setting) in a previously non-solid
nodule,  the  result  will  be  considered  positive  result  and
referral will be recommended.
No validated cut-off currently exists for the assessment of
growth in non-solid nodules. The doubling times of growing
non-solid (pure ground glass) nodules are expected to be a
median  VDT of  1,832  days  and  a  median  MDT of  1,556
days24. However, this includes benign entities as well as the
spectrum of pre-malignant and malignant adenocarcinoma.
VDT- or MDT-based management must be established in the
future, possibly in an approach combining both growth and
morphologic features. We propose a further 24 months of
follow-up for non-solid nodules that do not show any growth
(increase  in  volume  and/or  mass  <  25%)  or  any  newly
appearing  solid  components  (visible  in  a  mediastinal
window setting).
Self-reported participant data
To  assess  the  health  conditions  of  the  participants  and
explore  the  risk  factors  of  lung  nodules  or  lung  cancer,  the
participants’  self-reported  data  will  be  collected  at  baseline
and  after  1  year  by  using  epidemiological  questionnaires
before the low-dose CT scans. At baseline, data about general
characteristics,  risk  factors  of  lung  cancer,  and  health  status
of the participants were collected by trained staff during face-
to-face  interviews.  The  following  questionnaires  were  used
for the interview: (1) A questionnaire intended to obtain data
about  the  participant’s  general  characteristics,  medical
history,  and  known  risk  factors  of  lung  cancer  including
behavioral, environmental, and occupational risk factors; and
(2)  the  EQ5D-3L  questionnaire25,26.  One  year  after  the
baseline  investigation,  data  on  modified  risk  factors  and
health status will be collected again to determine any changes
in  behavior  and  health  conditions  by  using  a  simplified
questionnaire.
Follow-up
Follow-up  evaluation  will  be  performed  after  4  years  to
identify  participants  with  a  confirmed  diagnosis  of  lung
cancer.  Participants  diagnosed  with  lung  cancer  will  be
identified  through  the  hospital  information  system  during
the follow-up period. In case participants are diagnosed with
lung cancer in another hospital, participants or their relatives
will be contacted by phone to obtain diagnostic information
4 years after the baseline investigation. Therefore, a diagnosis
of  lung  cancer  can  be  clinically  confirmed  using  either
medical  records  or  self-reports  of  the  participants  or  their
relatives.
All  participants  will  be  invited  to  attend  a  follow-up
interview  with  qualified  staff  from  the  Department  of
Epidemiology  at  TJMUCIH.  The  staff  will  conduct  these
follow-up  interviews  with  both  active  and  passive
approaches. Phone calls will first be made to inquire about
the patient’s diagnosis of lung cancer, vital status, and any
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further examination undergone after the initial screening. If
there is no response to phone calls, the hospital information
system at TJMUCIH will be searched for matches to identify
patients recently admitted to receive medical care. In the case
of deceased patients, family members will be asked to provide
the date and cause of death. Established cancer registries and
death registries in Tianjin will also be used as a supplement to
identify any diagnosis of lung cancer and the vital status of
the patient.
Information will be collected using a short questionnaire,
mainly including the diagnosis date, hospital, type and stage
of lung cancer, surgery, cost of treatment, survival status, and
cause of death. Lung cancer will be classified as screening-
detected lung cancer  or  interval  lung cancer.  The former
refers to lung cancer detected during the first  year after a
positive screening test and the latter refers to lung cancer
detected during the first year after a negative screening test.
Outcomes
The  primary  outcome  is  the  diagnostic  performance  of  the
European volume-based management  protocol  as  compared
to the diameter-based protocol. The secondary outcomes are
(1) the difference between the classifications of lung nodules
according  to  the  diameter-based  and  volume-based
protocols, (2) the frequency of risk factors of lung cancer and
the overall health score among participants with and without
lung  nodules  as  well  as  the  prevalence  and  the  incidence  of
lung nodules, (3) the incidence of confirmed lung cancer and
related  mortality  and  its  influencing  factors,  and  (4)  the
expected  reduction  in  time  to  diagnosis  and  number  of
follow-up  CT  scans  when  incorporating  volume-based
management.
Data de-identification and storage
For each participant, a random number will be generated and
linked  to  an  existing  participant-number  from  the  hospital
records.  All  the  information  used  for  the  identification  of  a
participant (name, participant number, date of birth) will be
removed  from  the  dataset.  The  file  containing  the
information necessary for linkage of the randomly generated
numbers  and  the  participant-numbers  will  be  stored
separately  on  a  dedicated  NELCIN-B3  server  at  TJMUCIH
and backed up on an encrypted USB drive.
Data analyses
The  diagnostic  performance  of  the  volume-based  and
diameter-based  protocols  will  be  assessed  by  calculating  the
sensitivity,  specificity,  positive predictive value,  and negative
predictive value for the first and second rounds of screening.
The  sensitivity  will  be  calculated  by  dividing  the  number  of
true-positive  screening  results  (screening-detected  lung
cancers)  by  the  number  of  true  positive  and  false  negative
screening  results  (interval  cancers  detected  during  the  same
period).  The  specificity  will  be  calculated  by  dividing  the
number  of  true  negative  screening  results  by  the  number  of
true negative and false-positive screening results. The positive
predictive value will be calculated by dividing the number of
true-positive screening results by the number of true positive
and  false-positive  screening  results.  The  negative  predictive
value  will  be  calculated  by  dividing  the  number  of  true
negative screening results by the number of true negative and
false  negative  screening  results.  The  differences  in  lung
nodule  classification  between  the  volume-based  and
diameter-based  protocols  will  be  tested  using  the
McNemar–Bowker  test.  Relevant  risk  factors  related  to  the
presence  of  lung  nodules  will  be  identified  using  univariate
analysis and multivariate logistic regression. The relationship
between the presence of  lung nodules and the overall  health
status  will  be  tested  using  multiple  linear  regression.  The
expected  reduction  in  time  to  diagnosis  and  number  of
follow-up  CT  scans  for  the  true  positive  results  will  be
calculated for volume-based management.
Further research
In  this  population-based  cohort  study,  we  will  test  and
validate  the  efficacy  of  a  volume-based  protocol  for  the
management  of  screen-detected  lung  nodules  in  a  Chinese
population  in  terms  of  reducing  false-positive  results.  If  the
protocol  demonstrates  superiority  in  reducing  false-positive
results,  we  intend to  optimize  the  management  of  solid  and
part-solid  lung  nodules  detected  using  low-dose  CT  in  a
Chinese  context.  Furthermore,  we  intend  to  identify  the
relevant risk factors of lung cancer to optimize the criteria for
defining  high-risk  groups  that  might  benefit  from  CT
screening in a general Chinese population and to evaluate the
potential cost-effectiveness of low-dose CT screening for lung
cancer in China.
Discussion
Low-dose  CT  screening  for  lung  cancer  can  reduce  the
mortality of the disease12.  However, one of the downsides of
CT  screening  is  the  detection  of  large  numbers  of  benign
non-calcified  nodules,  potentially  obtaining  a  high  number
of false-positive results.
The routine evaluation of low-dose CT images for lung
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cancer in China has been based on assessing the diameter of
lung nodules18,27. In the current diameter-based protocol, a
large proportion of benign nodules require further work-up,
which may increase the radiation risk from more frequent
and higher-dose CT evaluations, the risk of complications
from invasive evaluations, and financial and psychological
burdens28. Lung nodule management based on volume and
VDT has proven effective in reducing the false-positive rate
of  low-dose  CT  screening  in  a  European  population11.
However, findings from European studies cannot necessarily
be directly translated to a Chinese population. To explore the
efficacy of the European CT screening protocol in China, we
designed this population-based cohort study as part of the
NELCIN-B3 project aiming to test and validate the diagnostic
performance of a European management protocol for lung
nodules  by  modeling  volume-based  management  in  a
Chinese population.
To  the  best  of  our  knowledge,  studies  examining  the
application  of  volume-based  management  in  a  Chinese
population are lacking. We will compare two well-defined
protocols for lung nodule management in CT screening for
lung cancer (the European volume-based protocol and an
American  NCCN diameter-based  protocol)  in  a  Chinese
population. Moreover, the secondary interpretation of CT
images  will  be  performed  with  blinding  to  the  primary
interpretation. Furthermore, the population-based design
allows further exploration of the risk factors of lung cancer.
The results  also have the potential  to be adapted to other
urban contexts in China. Therefore, we believe the results of
this  highly  feasible  study  will  greatly  contribute  to  the
optimization of early detection of lung cancer in China.
This  study  has  some  limitations.  First,  lung  cancer
diagnosis could be established in another hospital, preventing
access to the clinical records of the participants. In such cases,
we  will  contact  the  participants;  however,  recall  bias  is
unavoidable. Second, the inclusion criteria of patients having
no history of malignant tumour will be evaluated through a
face-to-face interview. Thus, patients who are unaware of a
previous malignant tumour diagnosis may be erroneously
included.
Ethical approval and consent to
participate
The  NELCIN-B3  project  in  China  is  led  by  Shanghai
Changzheng  Hospital,  which  is  affiliated  with  Second
Military  Medical  University.  TJMUCIH  is  a  hospital
participating in the NELCIN-B3 project. The ethical approval
for  NELCIN-B3  project  was  issued  by  the  committee  on
ethics  of  the  leading  institute,  namely  the  Committee  on
Ethics  of  Biomedicine  Research  of  Second  Military  Medical
University.  According  to  Chinese  legislation,  if  ethical
approval  is  provided  by  the  leading  institute  of  a  clinical
project,  other  participating  institutes  must  recognize  the
conclusion  of  the  ethical  committee  of  the  leading  institute;
hence,  acquiring  the  ethical  approval  of  each  institute  is
unnecessary29. Each participant will be asked to read and sign
an  informed  consent  form  that  introduces  the  screening
project, its benefits, potential harm, and confidentiality.
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Appendix 1.   Nodule parameters to be collected
Per Nodule Possible findings More detailed specification
1 Location Lung Left/Right Lung lobe
2 Location segment Lung segment
3 Slice number CT slice number Central in nodule
4 Location Peripheral Distance 2/3 from hilum
Central Within 1/3 of long hilum
Continued
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